Citations

Clear

4510 citation(s) found for "Scott, C".

Acute Kidney Injury and Outcomes in the Cardiac Intensive Care Unit: Insights from the Critical Care Cardiology Trials Network
Padkins, Mitchell , Papolos, Alexander , Kenigsberg, Benjamin B. , Katz, Jason N., Diepen, Sean van, Steverson, Alexandra K., Rose, Scott W. , Wang, Jeffrey, Park, Jeong‐Gun , Barsness, Gregory W. , Jentzer, Jacob Colin, Diepen, Sean van , Singam, N Sarma V , Padkins, Mitchell R , van Diepen, Sean , Jentzer, Jacob C , Singam, Narayana Sarma V. , Berg, David D. , Katz, Jason N , Bohula, Erin A. , Morrow, David A. , Jentzer, Jacob C.

Mayo Clinic

Journal of Intensive Care Medicine | April 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261440201 | PMID 41954488 Get It

Background Acute kidney injury (AKI) is associated with high morbidity and mortality in critically ill patients. Multicenter analyses describing the epidemiology of AKI in the cardiac intensive care unit (CICU) are scarce. Here, we describe the prevalence, predictors, and outcomes associated with AKI in a contemporary multicenter CICU population. Methods The Critical Care Cardiology Trials Network (CCCTN) is a collaboration of CICUs in North America coordinated by the TIMI Study Group (Boston, MA). We evaluated patient and hospital-level outcomes as a function of creatinine-only Kidney Disease: Improving Global Outcomes (KDIGO) AKI stage within the CCCTN registry. Logistic regression was used to assess associations with in-hospital mortality. Results Among 21 603 admissions, the overall prevalence of AKI was 23.7%, which was composed of KDIGO stage 1: 12.7%, stage 2: 1.7%, and stage 3: 9.2%. A higher prevalence and severity of AKI were seen in patients with baseline kidney disease, hypertension, or diabetes and in admissions with heart failure, cardiogenic shock, and cardiac arrest ( P < .001 for all). There was a stepwise increase in hospital mortality across AKI stages (stage 1: 23%, stage 2: 39%, stage 3: 42%; P < .0001). The increased risk of death associated with progressive AKI stage persisted after multivariate adjustment (adjusted OR: stage 1: 2.1, stage 2: 3.7, stage 3: 3.4). Conclusions AKI occurs in 1 in 4 admissions to the CICU, and a higher AKI stage is incrementally associated with in-hospital mortality, highlighting a need to develop strategies to mitigate AKI and its complications.
Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R. , Bharat, A., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Durm, Gregory A. , Gettinger, S., Gubens, Matthew A. , Lackner, Rudy P., Levy, B., Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn, Patil, Tejas, Riess, Jonathan W. , Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Stevenson, James, Tam, A. , Yau, Edwin , Gregory, Kristina, Hang, Lisa E., Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bharat, Ankit , Dowell, Jonathan E. , Gettinger, Scott , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Ng, Thomas, Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yun, Karen M. , Gregory, Kristina M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2026.0017 | PMID 41956107 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable biomarkers.
Primary Care Clinicians’ Attitudes on Digital Care Collaborative Management for Substance Use Disorders
Lai, Benjamin , Bormann, N. L., Arndt, Stephan, Smith, Jamie, Stoppel, Cynthia , Tuen, Kelsey, Cox, Danielle, Breitinger, Scott , Williams, Mark, Paul, Margaret, Lai, Benjamin , Bormann, Nicholas L. , Arndt, Stephan , Paul, Margaret M. , Oesterle, Tyler

Mayo Clinic

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | April 9, 2026 | Volume: 63 | Issue: No issue available | Pages: No page available

10.1177/00469580261440482 | PMID 41954165 Get It

Substance use disorders (SUD) remain a significant source of morbidity and mortality in the United States, and access to treatment continues to be inadequate. Primary Care Clinicians (PCCs) are well-positioned to provide long-term SUD care for patients. However, multiple provider-level barriers exist. Collaborative Care Management (CoCM) has proven successful in supporting PCCs in treating psychiatric conditions, such as depression. Our group proposes an addiction-focused modified CoCM that leverages telemedicine and an electronic platform (Senyo) into primary care. This study assesses PCCs’ attitudes toward this proposed model and their likelihood (with support) of prescribing medications for alcohol and opioid use disorder. To achieve this, an anonymized and confidential electronic survey was deployed to all 489 of our institutions’ PCCs. Eighty-five completed the survey (17.4% response); the majority (94%) agreed that digital CoCM for SUD will be helpful for their practice, and 85% expressed agreement that such a model will increase their confidence and likelihood to prescribe anti-craving medications. Additionally, we found that PCCs’ comfort level in addressing SUD with patients is not associated with years in practice, clinician type (attending physicians, resident/fellow physicians, nurse practitioner or physician assistant), or their perception of currently available SUD treatment resources. Future work to evaluate practice changes, including rates of anti-craving medication prescribing and SUD-treatment outcomes after implementation of our digital CoCM will prove useful in determining the effectiveness of this model.
Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer
Ganti, Ashwin , McGarrah, Patrick W. , Bayne, H. Fuentes, Fazer-Posorske, Casey , Baral, Binav, Ma, Daniel J., Neben-Wittich, M.A. , Wilson, Jessica , Moore, Eric J., Tasche, Kendall K. , Abel, Katie M. Van, Foster, Nathan R. , Price, Katharine A. , Daniel, J. , Fuentes, Harry E , Fuentes, Harry E , Baral, Binav , Ma, Daniel , Lester, Scott C. , Neben-Wittich, Michelle A, Wilson, Jessica M , Van Abel, Katie M, Price, Katharine A R , McGarrah, Patrick , Routman, David M. , Price, Daniel L. , Moore, Eric J. , Abel, Katie M. Van, Yin, Linda X.

Mayo Clinic

Viruses | April 8, 2026 | Volume: 18 | Issue: 4 | Pages: 446

10.3390/v18040446 | PMID 42043235 Get It

Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%; p = 0.5241). There were also no differences in hospitalizations for adverse events (38.9% in TPF vs. 40.5% in platinum doublet, p = 0.907) or recurrence (11.1% in TPF vs. 2.7% in platinum doublet, p = 0.198). The 5-year OS was 84.6% in the TPF group and 81.5% in the platinum doublet group (p = 0.581). Induction platinum doublet regimens offer comparable OS, response, and hospitalization rates to TPF in locally advanced HPV(+) OPSCC. Induction with a platinum doublet may be a viable de-escalation strategy for patients who are not candidates for TPF.
Multi-Contrast MRI Inputs Enable Self-Consistent Tissue Segmentation & Robust Perivascular Space Identification
Gunter, Jeffrey L. , Preboske, Gregory M., Persons, Benjamin D., Przybelski, Scott A. , Petersen, Ronald, Jack, Clifford R, Gunter, Jeffrey L , Persons, Benjamin, Schwarz, Christopher G. , Low, Audrey , Vemuri, Prashanthi , Jack, Clifford R.

Mayo Clinic

No container title available | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.03.716409 | PMID 41993560 Get It

Abstract Different MRI image contrasts are designed to highlight various tissue properties and combining them allows extension of probabilistic segmentation beyond the commonly used “gray-white-CSF” models. This work describes a fully automated method that combines T1-weighted, T2-FLAIR, and conventional T2-weighted images to provide internal consistency across prediction of tissue segmentations including segmentation of superficial and deep gray matter, white matter hyperintensities, and MR-visible perivascular spaces. Results from 773 imaging datasets from 403 participants in the Mayo Clinic Study of Aging and Mayo Clinic Alzheimer’s Disease Research Center (ADRC) are presented.
Improving Diagnostic Accuracy of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through a Point-of-Care Clinical Algorithm
Seltzer, Jaime, Grach, Stephanie L. , Eggers, Scott D.Z. , Redetzke, Melissa M., Mau, Katie, Chon, Tony Y. , Seltzer, J. L. , Seltzer, Jaime , Eggers, Scott D , Mau, Katie J, Grach, Stephanie L , Ganesh, Ravindra

Mayo Clinic

International Journal of Environmental Research and Public Health | April 6, 2026 | Volume: 23 | Issue: 4 | Pages: 460

10.3390/ijerph23040460 | PMID 42074399 Get It

Despite the increasing prevalence and median severity of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), medical education on the disease is scant, leading to a diagnostic crisis in which the majority of people with ME/CFS are undiagnosed. We created a care process algorithm in AskMayoExpert accessible to all Mayo Clinic medical providers as a source for information on diagnosis and management of ME/CFS. To evaluate whether the algorithm was associated with improved diagnostic accuracy, we compared concordance before versus after the algorithm was introduced, where concordance was defined as agreement between an appropriately coded referral to Mayo Clinic’s Chronic Fatigue Specialty Clinic and the specialty clinic with an expert diagnosis of ME/CFS. Referrals to the Chronic Fatigue Specialty Clinic increased overall and were more likely to show concordance between specialist diagnosis and referral after the introduction of the ME/CFS AskMayoExpert algorithm. Particularly in diseases that are prevalent and poorly understood, a point-of-care clinical tool may offer just-in-time opportunities to improve diagnosis and management.
The longevity effects of reduced IGF-1 signaling depend on the stability of the mitochondrial genome
Shemtov, Sarah J. , McGann, Eric, Carrillo, Lucy , Lee, Sangmin , Anson, Herbert, Chung, Claire S, Weinert, Jaye L., Anagnostou, Maria-Eleni, Lai, Guan-Ju, Verheijen, Bert M. , Wan, Junxiang , Vorobyova, Ivetta, Sanchez-Contreras, Monica, Conover, Cheryl A. , Thorwald, Max A. , Cohen, P., Kennedy, Scott R. , Goût, Jean-François , Haroon, Suraiya , Vermulst, Marc , Hwang, Eric , Chung, Claire S , Weinert, Jaye L , Lai, Guan-Ju D , Conover, Cheryl A , Thorwald, Max A , Cohen, Pinchas , Kennedy, Scott R , Gout, Jean-François , Vermulst, Marc , Anagnostou, Maria‐Eleni, Sánchez-Contreras, Mónica , Cohen, Pinchas

Mayo Clinic

Science Advances | April 3, 2026 | Volume: 12 | Issue: 14 | Pages: No page available

10.1126/sciadv.aea4279 | PMID 41931604 Get It

Suppression of insulin-like growth factor-1 (IGF-1) signaling extends mammalian life span and protects against a range of age-related diseases. Unexpectedly, we found that reduced IGF-1 signaling fails to extend the life span of mitochondrial mutator mice. Most of the longevity pathways that are normally initiated by IGF-1 suppression were either blocked or blunted in the mutator mice. These observations suggest that the prolongevity effects of IGF-1 suppression critically depend on the integrity of the mitochondrial genome, revealing an unexpected hierarchy in the pathways that control mammalian aging. Together, these findings deepen our understanding of the interactions between the hallmarks of aging and underscore the need for interventions that preserve the integrity of the mitochondrial genome.
Abstract 4560: CTPS1 as a metabolic vulnerability and novel therapeutic target in breast and ovarian cancer
Wang, Xiyin, Emch, Michael, Voll, Lauren, Epp, Rebecca, Rodman, Esther , Odell, Noa , Smith, Hannah , Pearson, Nicole A, Hou, X, Goetz, M. P., Weroha, S. John, Beer, Phillip, Hawse, John R., Emch, Michael J. , Kaufmann, Scott H. , Weroha, S. John

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4560-4560

10.1158/1538-7445.am2026-4560 Get It

Abstract Breast and ovarian cancers are major causes of cancer mortality in women with frequent relapse after curative intent treatment, underscoring the need for novel therapeutics. To this end, we identified CTPS1 as an essential gene in multiple breast and ovarian cancer models, including those resistant to chemotherapy and PARP inhibitors. CTPS1 and CTPS2 are responsible for de novo synthesis of cytidine triphosphate (CTP) which is required for DNA/RNA polymerization, phospholipid synthesis and protein glycosylation. We found CTPS1 to be the predominant isoform expressed in cancer cells, with significantly higher levels in advanced and resistant disease models compared to normal tissue, benign lesions and treatment naïve cancers. Using CTPS1 siRNAs and CTPS1-dTAG (degradation tag) cell lines, we discovered that depletion of CTPS1 induces S-phase cell cycle arrest followed by apoptosis. Leveraging a first-in-class, highly selective, and orally bioavailable CTPS1 inhibitor (STP938) developed by Step Pharma, we identified nanomolar IC50 values across a panel of cell lines, both in 2D and 3D culture systems, and potent anti-neoplastic activity ex vivo and in vivo using patient-derived xenograft (PDX) models. STP938 also synergized with standard-of-care chemotherapy agents and PARP inhibitors, including in therapy-resistant models. Given the essentiality of CTP for biosynthetic processes, we performed bulk and single cell RNA-seq, total and phospho-proteomics, metabolomics, and lipidomic strategies to examine changes induced by acute and chronic STP938 exposure. This revealed that cancer cells are able to overcome pharmacologic CTPS1 inhibition by rewiring of pyrimidine and purine synthesis pathways, upregulation of the pentose phosphate pathway, and extensive remodeling of lipid synthesis pathways including shifts in PC/PE content, increased lysophospholipid production, and altered mitochondrial lipid composition (decreased cardiolipin and increased PG). To identify genetic drivers of STP938 resistance and synthetic lethal vulnerabilities, we performed a genome-wide CRISPR knockout screen together with a PRISM drug sensitivity screen. Genes regulating dNTP biosynthesis, S-phase progression, and RNA processing were identified as primary escape mechanisms, while DHODH inhibitors, purine and nucleoside analogs, and mitosis modifiers were implicated as synthetic lethal opportunities. Notably, we discovered that 25% of ovarian tumors lack CTPS2 protein expression, suggesting near complete reliance on CTPS1 for survival. Thus, a Phase 1a/b clinical trial of STP938 (NCT06297525) has been initiated, including an expansion cohort for patients with CTPS2-null ovarian tumors. These laboratory discoveries and ongoing clinical efforts aim to enable broader uptake of this novel therapeutic approach to improve long-term outcomes in patients with CTPS1-dependent disease. Citation Format: Xiyin Wang, Michael Emch, Lauren Voll, Rebecca Epp, Esther Rodman, Noa Odell, Hannah Smith, Nicole Pearson, Xiaonan Hou, Matthew Goetz, Scott Kaufmann, S. John Weroha, Phillip Beer, John Hawse. CTPS1 as a metabolic vulnerability and novel therapeutic target in breast and ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4560.
Abstract 2597: Baseline cfDNA fragmentomics identifies multiple myeloma patients at risk of early progression
Abelman, Dor , Eagles, Jenna , Wong, Aimée A., Shah, Saumil , Bruce, Jeffrey, Campos, Cecília Bonolo de , White, Darrell , Sandhu, Irwindeed, Song, Kevin , Kumar, Shaji Kunnathu, Murugesan, Alli , Reiman, Tony , Stewart, A. Keith, Trudel, Suzanne , Pugh, Trevor J., Wong, Aimee, Pedersen, Stephanie , Scott, David S. , Chow, Signy , Sandhu, Irwin, Braggio, Esteban , Stewart, A. Keith , Pugh, Trevor J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2597-2597

10.1158/1538-7445.am2026-2597 Get It

Abstract Introduction: Early relapse limits durable remissions in multiple myeloma (MM). Cell-free DNA (cfDNA) fragment patterns capture tumor burden and nucleosome positioning. We tested whether a fragmentomics signature trained at MRD time points stratifies progression-free survival (PFS) when applied to pretreatment plasma. Methods: We performed 30-40× whole-genome sequencing of plasma cfDNA from 43 newly diagnosed MM patients, with 65 additional MRD timepoint samples from 41 of those patients (post-ASCT n=30; 1-year maintenance n=30; other maintenance n=5) across eight Canadian sites (TFRIM4 and IMMAGINE studies) and one U.S. site (Mayo SPORE). MRD testing used multiparameter flow cytometry for all follow-up samples (n=65) and clonoSEQ in a subset (n=31). Logistic and elastic-net models were trained at MRD timepoints on fragmentomics features (short-fragment burden; a combined model integrating fragment-length distributions with inferred nucleosome positioning at MM-specific chromatin accessibility regions [Ordoñez et al., Genome Res. 2020]). A decision threshold was fixed by the Youden index during training and applied unchanged to diagnosis samples. PFS was analyzed by Kaplan-Meier, log-rank, and Cox models. Results: After a median follow-up of 49.1 months, 16 of 43 patients (37%) progressed. Using the prespecified locked threshold, patients classified as MRD+ by the proportion-of-short-fragments model had significantly shorter PFS than MRD- patients (HR = 5.12; 95% CI 1.16-22.57; log-rank p = 0.016), with median PFS of 49.2 months for MRD+ cases versus not reached for the MRD- group. Fixed-horizon PFS favored MRD- samples at 24/36/48 months (100/94/87% vs 85/81/53% for MRD+). A combined model integrating weighted fragment lengths with inferred nucleosome positioning also separated outcomes (log-rank p=0.054); the Cox HR was not estimable because no MRD- patients relapsed. At 24, 36, and 48 months, baseline MRD positivity by the short-fragment model identified 100%, 83%, and 86% of patients who relapsed within those intervals (specificity 44%, 43%, and 52%), while the combined model detected all early relapses across the same horizons (specificity 15-21%), indicating consistently high sensitivity but modest specificity for predicting early progression. Conclusions: A cfDNA fragmentomics signature trained at MRD time points stratified PFS when applied to diagnostic plasma, identifying patients at risk of early relapse. Short-fragment burden was most discriminative, and a combined model with nucleosome positioning recapitulated it with higher sensitivity, albeit lower specificity. These data support cfDNA fragmentomics as a practical liquid-biopsy risk biomarker in MM and suggest higher signals may proxy aggressive disease with greater tumor shedding and chromatin disorganization. Future work will validate findings in larger cohorts and integrate cytogenetic and immune features. Citation Format: Dor David Abelman, Jenna Eagles, Aimee Wong, Saumil Shah, Jeffrey Bruce, Stephanie Pedersen, David S. Scott, Cecilia Bonolo de Campos, Signy Chow, Darrell White, Irwindeed Sandhu, Kevin Song, Esteban Braggio, Shaji Kunnathu Kumar, Alli Murugesan, Tony Reiman, A. Keith Stewart, Suzanne Trudel, Trevor J. Pugh. Baseline cfDNA fragmentomics identifies multiple myeloma patients at risk of early progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2597.
Abstract 7636: A rare multipotent peg-like epithelial cell is a candidate cell-of-origin for high-grade serous ovarian cancer
Yang, Wenmei, Zhao, Hui , Feng, Liang, Song, Jianning, Schaufelberger, Kenneth, Weroha, S. John, Gaspar-Maia, Alexandre, Bakkum-Gamez, Jamie, Ritting, Megan L. , Aalam, Syed Mohammed Musheer , Dumbravă, Mihai , Ismail, Wazim Mohammed , Weroha, S. John, Kaufmann, Scott H. , Gaspar‐Maia, Alexandre , Sherman, Mark E. , Bakkum‐Gamez, Jamie N. , Kannan, Nagarajan

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7636-7636

10.1158/1538-7445.am2026-7636 Get It

Abstract High-grade serous ovarian cancer (HGSOC), the most prevalent and lethal ovarian cancer subtype, is typically diagnosed at an advanced stage due to the absence of effective early detection strategies. Mounting evidence indicates that HGSOC originates from the fallopian tube (FT), particularly from secretory epithelial cells in the fimbria. However, incomplete understanding of the cellular and molecular origins of HGSOC continues to hinder early interception efforts. To address this, we established a clinically and genetically annotated living FT organoid biobank at Mayo Clinic, representing over 200 patient donors. Using optimized enrichment protocols, we isolated FT epithelial stem/progenitor cells from tissue and Tao brushings, generating organoids independent of anatomical site or laterality that recapitulate native FT epithelial architecture and lineage differentiation. We applied integrated multi-omic analyses, including single-cell RNA sequencing, single-nucleus RNA/ATAC sequencing, and bulk RNA-seq, across fresh cells and organoids. Integration with public datasets produced the largest single-cell atlas of normal and high-risk FTs to date. This analysis defined high-specificity gene signatures for secretory and multiciliated lineages that outperform canonical lineage markers (e.g. PAX8, FOXJ1), identified lineage-defining transcription factors and regulatory networks, and showed concordant protein expression in the human FT epithelium. Notably, subcluster-level analysis revealed a rare hybrid epithelial-mesenchymal population transcriptionally and proteomically aligned with the mesenchymal-like subtype of HGSOC. Spatial immunoprofiling demonstrated that these cells express multiple defining markers and reside above the basement membrane, intercalated between epithelial cells and lack luminal contact, reminiscent of the histologically described peg cell population. Comparative analyses with fetal mesonephric tissues uncovered developmental parallels, and this population was stably maintained in 3D organoid cultures, providing a robust ex-vivo model to study early transformation. Together, our findings identify a rare, multipotent epithelial population with mesenchymal features as a candidate origin for mesenchymal-like HGSOC and establish the FT organoid biobank as a powerful platform for mechanistic and translational studies in ovarian carcinogenesis. Citation Format: Megan L. Ritting, Wenmei Yang, Syed Mohammed Musheer Aalam, Hui Zhao, Liang Feng, Jianning Song, Mihai G. Dumbrava, Wazim M. Ismail, Kenneth Schaufelberger, S. John Weroha, Scott H. Kaufmann, Alexandre Gaspar-Maia, Mark E. Sherman, Jamie N. Bakkum-Gamez, Nagarajan Kannan. A rare multipotent peg-like epithelial cell is a candidate cell-of-origin for high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7636.